HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ursodeoxycholic acid for adjuvant therapy with extracorporeal shock wave lithotripsy of gallstones.

Abstract
Extracorporeal shock wave lithotripsy (ESWL) of gallstones is a new and experimental treatment. Recent data seem to indicate that the use of ursodeoxycholic acid (UDCA) after ESWL may optimize the results of the shock wave treatment. Most of the published data on the clinical use of such therapy emanate from two studies conducted in West Germany in approximately 300 patients. These subjects received combination therapy with UDCA and chenodeoxycholic acid (CDCA) before and after ESWL. The stone fragments gradually disappeared by 18 months after lithotripsy. No adverse effects attributable to the UDCA-CDCA treatment were noted. Several considerations support the view that adjuvant chemical dissolution therapy will be necessary for best results with ESWL, including compatibility of the rate of stone dissolution postlithotripsy with that of chemical dissolution rather than mechanical ejection; the common presence of cholesterol-supersaturated bile in gallstone patients, promoting reconglomeration of fragments; and decreased contractility of the gallbladder, which may improve after successful cholelitholytic therapy with UDCA. Placebo-controlled studies on the use of UDCA with ESWL are currently being conducted.
AuthorsH Fromm
JournalJournal of clinical gastroenterology (J Clin Gastroenterol) Vol. 10 Suppl 2 Pg. S18-21 ( 1988) ISSN: 0192-0790 [Print] UNITED STATES
PMID3062080 (Publication Type: Clinical Trial, Journal Article, Review)
Chemical References
  • Deoxycholic Acid
  • Chenodeoxycholic Acid
  • Ursodeoxycholic Acid
Topics
  • Chenodeoxycholic Acid (therapeutic use)
  • Cholelithiasis (therapy)
  • Clinical Trials as Topic
  • Deoxycholic Acid (analogs & derivatives)
  • Germany, West
  • Humans
  • Lithotripsy
  • Ursodeoxycholic Acid (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD